Challenges Associated with Route of Administration in Neonatal Drug Delivery

Clinical Pharmacokinetics

Volumn 55, Issue 2, 2016, Pages 185-196

  Linakis, Matthew W ^a,b   Roberts, Jessica K ^a   Lala, Anita C ^c   Spigarelli, Michael G ^a   Medlicott, Natalie J ^d   Reith, David M ^c   Ward, Robert M ^a,e   Sherwin, Catherine M T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

AEROSOL; BIOAVAILABILITY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAPULMONARY DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METERED DOSE INHALER; NEBULIZER; NEONATAL VENTILATOR; NEWBORN; NEWBORN CARE; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PARTICLE SIZE; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; STOMACH PH; SUBCUTANEOUS DRUG ADMINISTRATION; TECHNOLOGY; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; INFANT, NEWBORN; PHARMACEUTICAL PREPARATIONS;

EID: 84958775719     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0313-z     Document Type: Review

References (143)

1. Khatri N, Misra A. Applications of polymers in parenteral drug delivery. In: Misra A, Shahiwala A, editors. Applications of polymers in drug delivery. Shrewsbury: Smithers Rapra; 2014.
2. Development of paediatric medicines: points to consider in formulation annex 5. WHO Technical Report Series. Geneva: World Health Organization; 2012. p. 1–29.
3. Pein M, Preis M, Eckert C, Kiene FE. Taste-masking assessment of solid oral dosage forms—a critical review. Int J Pharm. 2014;465(1–2):239–54.
4. Maniruzzaman M, Boateng JS, Chowdhry BZ, Snowden MJ, Douroumis D. A review on the taste masking of bitter APIs: hot-melt extrusion (HME) evaluation. Drug Dev Ind Pharm. 2014;40(2):145–56.
5. Papai K, Budai M, Ludanyi K, Antal I, Klebovich I. In vitro food–drug interaction study: which milk component has a decreasing effect on the bioavailability of ciprofloxacin? J Pharm Biomed Anal. 2010;52(1):37–42.
6. Knippa A. PN nursing care of children. Stilwell (KS): Assessment Technologies Institute; 2011.
7. Klingmann V. Acceptability testing of minitablets from neonates to pre-school children. 6th European Paediatric Formulation Initiative Conference; 17–18 Sep 2014; Athens.
8. Avery GB, Randolph JG, Weaver T. Gastric acidity in the first day of life. Pediatrics. 1966;37(6):1005–7.
9. Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology: extensive interindividual variability despite limited size. J Pediatr Pharmacol Ther. 2011;16(3):170–84.
10. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55(5):667–86.
11. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.
12. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077–97.
13. Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants: a population pharmacokinetic modelling approach. Fundam Clin Pharmacol. 2014;28(4):465–71.
14. Silverio J, Poole JW. Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics. 1973;51(3):578–80.
15. Koren G. Therapeutic drug monitoring principles in the neonate. National Academy of Clinical Biochemistry. Clin Chem. 1997;43(1):222–7.
16. Carlos MA, Babyn PS, Marcon MA, Moore AM. Changes in gastric emptying in early postnatal life. J Pediatr. 1997;130(6):931–7.
17. Czinn SJ, Blanchard S. Gastroesophageal reflux disease in neonates and infants: when and how to treat. Paediatr Drugs. 2013;15(1):19–27.
18. Hillemeier AC, Lange R, McCallum R, Seashore J, Gryboski J. Delayed gastric emptying in infants with gastroesophageal reflux. J Pediatr. 1981;98(2):190–3.
19. Martinussen M, Brubakk AM, Linker DT, Vik T, Yao AC. Mesenteric blood flow velocity and its relation to circulatory adaptation during the first week of life in healthy term infants. Pediatr Res. 1994;36(3):334–9.
20. Martinussen M, Brubakk AM, Vik T, Yao AC. Mesenteric blood flow velocity and its relation to transitional circulatory adaptation in appropriate for gestational age preterm infants. Pediatr Res. 1996;39(2):275–80.
21. Nankervis CA, Giannone PJ, Reber KM. The neonatal intestinal vasculature: contributing factors to necrotizing enterocolitis. Semin Perinatol. 2008;32(2):83–91.
22. Reber KM, Mager GM, Miller CE, Nowicki PT. Relationship between flow rate and NO production in postnatal mesenteric arteries. Am J Physiol Gastrointest Liver Physiol. 2001;280(1):G43–50.
23. Nankervis CA, Nowicki PT. Role of nitric oxide in regulation of vascular resistance in postnatal intestine. Am J Physiol. 1995;268(6 Pt 1):G949–58.
24. Reed MD. The ontogeny of drug disposition: focus on drug absorption, distribution, and excretion. Drug Inf J. 1996;30:1129–34.
25. Shankaran S, Kauffman RE. Use of chloramphenicol palmitate in neonates. J Pediatr. 1984;105(1):113–6.
26. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3(2):108–27.
27. Hill JM, Maloney A, Stephens K, Adrezin RS, Eisenfeld L. Stethoscope for monitoring neonatal abdominal sounds. Int J Mod Eng. 2008;9(1):5.
28. Dumas J, Hill KM, Adrezin RS, et al. Feasibility of an electronic stethoscope system for monitoring neonatal bowel sounds. Conn Med. 2013;77(8):467–71.
29. van Kalken CK, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol. 1992;141(5):1063–72.
30. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993;122(1):137–44.
31. Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003;142(1):47–52.
32. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995;58(5):492–7.
33. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60(1):14–24.
34. Ince I, Knibbe CA, Danhof M, de Wildt SN. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet. 2013;52(5):333–45.
35. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol. 2002;53(4):390–2.
36. Pacifici GM. Clinical pharmacology of midazolam in neonates and children: effect of disease-a review. Int J Pediatr. 2014;2014:309342.
37. Gritz EC, Bhandari V. The human neonatal gut microbiome: a brief review. Front Pediatr. 2015;3:17.
38. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014;6(237):237ra65.
39. Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. Acta Paediatr. 2009;98(2):229–38.
40. Scholtens PA, Oozeer R, Martin R, Amor KB, Knol J. The early settlers: intestinal microbiology in early life. Annu Rev Food Sci Technol. 2012;3:425–47.
41. Stewart CJ, Marrs EC, Nelson A, et al. Development of the preterm gut microbiome in twins at risk of necrotising enterocolitis and sepsis. PLoS One. 2013;8(8):e73465.
42. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181(3):555–62.
43. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science. 1983;220(4594):325–7.
44. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305(14):789–94.
45. Carmody RN, Turnbaugh PJ. Host–microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest. 2014;124(10):4173–81.
46. Broussard L. Small size, big risk: preventing neonatal and pediatric medication errors. Nurs Womens Health. 2010;14(5):405–8.
47. D’Antonio YC, Cohen MR. Pediatric medication errors. In: Cohen MR, editor. Medication errors: causes, prevention, and risk management. Sudbury (MA): Jones and Bartlett Publishers, Inc.; 1999.
48. Lass J, Naelapaa K, Shah U, et al. Hospitalised neonates in Estonia commonly receive potentially harmful excipients. BMC Pediatr. 2012;12:136.
49. Allegaert K, Vanhaesebrouck S, Kulo A, et al. Prospective assessment of short-term propylene glycol tolerance in neonates. Arch Dis Child. 2010;95(12):1054–8.
50. Salunke S, Brandys B, Giacoia G, Tuleu C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2—the pilot version. Int J Pharm. 2013;457(1):310–22.
51. Turner MA, Duncan J, Shah U, et al. European study of neonatal exposure to excipients: an update. Int J Pharm. 2013;457(1):357–8.
52. Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 2014;168(2):106–8.
53. Usher R, Shephard M, Lind J. The blood volume of the newborn infant and placental transfusion. Acta Paediatr. 1963;52:497–512.
54. Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child. 2014;99(6):590–4.
55. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM, Medlicott NJ. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J Pharm Pharmacol. 2009;61(4):465–71.
56. Medlicott NJ, Reith DM, McCaffrey F, Krittaphol W, Broadbent RS. Delayed delivery of intravenous gentamicin in neonates: impact of infusion variables. J Pharm Pharmacol. 2013;65(3):370–8.
57. Colacchio K, Deng Y, Northrup V, Bizzarro MJ. Complications associated with central and non-central venous catheters in a neonatal intensive care unit. J Perinatol. 2012;32(12):941–6.
58. Katheria AC, Fleming SE, Kim JH. A randomized controlled trial of ultrasound-guided peripherally inserted central catheters compared with standard radiograph in neonates. J Perinatol. 2013;33(10):791–4.
59. Panagiotounakou P, Antonogeorgos G, Gounari E, Papadakis S, Labadaridis J, Gounaris AK. Peripherally inserted central venous catheters: frequency of complications in premature newborn depends on the insertion site. J Perinatol. 2014;34(6):461–3.
60. Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609–13.
61. Evans C, Dixon A. Intravenous therapy: practice issues. Infant. 2006;2(4):133–6.
62. Robinson CA, Sawyer JE. Y-site compatibility of medications with parenteral nutrition. J Pediatr Pharmacol Ther. 2009;14(1):48–56.
63. Kenner C, Lott JW. Comprehensive neonatal care: an interdisciplinary approach. 4th ed. St. Louis (MO): Elsevier Health Sciences; 2007.
64. Jew RK, Owen D, Kaufman D, Balmer D. Osmolality of commonly used medications and formulas in the neonatal intensive care unit. Nutr Clin Pract. 1997;12(4):158–63.
65. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593–7.
66. Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982;307(22):1384–8.
67. Ward RM, Kern SE. Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ther. 2009;86(6):585–7.
68. Uppal N, Yasseen B, Seto W, Parshuram CS. Drug formulations that require less than 0.1 mL of stock solution to prepare doses for infants and children. CMAJ. 2011;183(4):E246–8.
69. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol. 2003;17(3):281–99.
70. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(RR2):1–64.
71. Khambalia AZ, Roberts CL, Bowen JR, Nassar N. Maternal and infant characteristics by mode of vitamin K prophylaxis administration. J Paediatr Child Health. 2012;48(8):665–8.
72. Ipema HJ. Use of oral vitamin K for prevention of late vitamin k deficiency bleeding in neonates when injectable vitamin K is not available. Ann Pharmacother. 2012;46(6):879–83.
73. Bellieni CV, Aloisi AM, Ceccarelli D, et al. Intramuscular injections in newborns: analgesic treatment and sex-linked response. J Matern Fetal Neonatal Med. 2013;26(4):419–22.
74. Patel IH, Weinfeld RE, Konikoff J, Parsonnet M. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother. 1982;21(6):957–62.
75. Powell KR, Mawhorter SD. Outpatient treatment of serious infections in infants and children with ceftriaxone. J Pediatr. 1987;110(6):898–901.
76. Shah VS, Taddio A, Hancock R, Shah P, Ohlsson A. Topical amethocaine gel 4% for intramuscular injection in term neonates: a double-blind, placebo-controlled, randomized trial. Clin Ther. 2008;30(1):166–74.
77. Liaw JJ, Zeng WP, Yang L, Yuh YS, Yin T, Yang MH. Nonnutritive sucking and oral sucrose relieve neonatal pain during intramuscular injection of hepatitis vaccine. J Pain Symptom Manag. 2011;42(6):918–30.
78. Hensel D, Morson GL, Preuss EA. Best practices in newborn injections. MCN Am J Matern Child Nurs. 2013;38(3):163–7 (quiz 168–169).
79. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics. 2001;108(4):934–42.
80. Costa S, Romagnoli C, Zuppa AA, et al. How to administrate erythropoietin, intravenous or subcutaneous? Acta Paediatr. 2013;102(6):579–83.
81. Ghadially R, Shear NH. Topical therapy and percutaneous absorption. In: Fletcher J, editor. Pediatric pharmacology: therapeutic principles in practice. 2nd ed. Philadelphia: W.B. Saunders Company; 1992. p. 72–7.
82. Choonara I. Percutaneous drug absorption and administration. Arch Dis Child. 1994;71(2):F73–4.
83. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000;106(3 Suppl):S128–38.
84. West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant skin. J Investig Dermatol. 1981;76(3):147–50.
85. Powell H, Swarner O, Gluck L, Lampert P. Hexachlorophene myelinopathy in premature infants. J Pediatr. 1973;82(6):976–81.
86. Dilly SA. Scanning electron microscope study of the development of the human respiratory acinus. Thorax. 1984;39(10):733–42.
87. Everard ML. Inhalation therapy for infants. Adv Drug Deliv Rev. 2003;55(7):869–78.
88. Amirav I, Newhouse MT. Aerosol therapy in infants and toddlers: past, present and future. Expert Rev Respir Med. 2008;2(5):597–605.
89. Amirav I, Newhouse MT. Deposition of small particles in the developing lung. Paediatr Respir Rev. 2012;13(2):73–8.
90. Schuepp KG, Jauernig J, Janssens HM, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med. 2005;18(2):225–35.
91. Kohler E, Jilg G, Avenarius S, Jorch G. Lung deposition after inhalation with various nebulisers in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2008;93(4):F275–9.
92. Fok TF, Monkman S, Dolovich M, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1996;21(5):301–9.
93. Sood BG, Peterson J, Malian M, et al. Jet nebulization of prostaglandin E1 during neonatal mechanical ventilation: stability, emitted dose and aerosol particle size. Pharmacol Res. 2007;56(6):531–41.
94. Fink JB. Delivery of inhaled drugs for infants and small children: a commentary on present and future needs. Clin Ther. 2012;34(11):S36–45.
95. Ballard J, Lugo RA, Salyer JW. A survey of albuterol administration practices in intubated patients in the neonatal intensive care unit. Respir Care. 2002;47(1):31–8.
96. Lugo RA, Kenney JK, Keenan J, Salyer JW, Ballard J, Ward RM. Albuterol delivery in a neonatal ventilated lung model: nebulization versus chlorofluorocarbon- and hydrofluoroalkane-pressurized metered dose inhalers. Pediatr Pulmonol. 2001;31(3):247–54.
97. Fok TF, Lam K, Ng PC, et al. Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J. 1998;12(1):159–64.
98. Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419–32.
99. El-Gendy N, Kaviratna A, Berkland C, Dhar P. Delivery and performance of surfactant replacement therapies to treat pulmonary disorders. Ther Deliv. 2013;4(8):951–80.
100. Sweet DG, Halliday HL. The use of surfactants in 2009. Arch Dis Child Educ Pract Ed. 2009;94(3):78–83.
101. Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink R. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol. 2002;29(8):661–5.
102. Hughes WT, Sillos EM, LaFon S, et al. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. J Infect Dis. 1998;177(4):1046–56.
103. van’t Veen A, Mouton JW, Gommers D, Lachmann B. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol. 1996;119(6):1145–8.
104. Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics. 2008;121(5):e1310–8.
105. Ari A, Restrepo RD. Aerosol delivery device selection for spontaneously breathing patients: 2012. Respir Care. 2012;57(4):613–26.
106. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child. 1999;81(2):163–5.
107. Murakami G, Igarashi T, Adachi Y, et al. Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy. 1990;64(4):383–7.
108. Moss ML. The veloepiglottic sphincter and obligate nose breathing in the neonate. J Pediatr. 1965;67(2):330–1.
109. Djupesland PG, Skretting A, Winderen M, Holand T. Bi-directional nasal delivery of aerosols can prevent lung deposition. J Aerosol Med. 2004;17(3):249–59.
110. Guerin C, Fassier T, Bayle F, Lemasson S, Richard JC. Inhaled bronchodilator administration during mechanical ventilation: how to optimize it, and for which clinical benefit? J Aerosol Med Pulm Drug Deliv. 2008;21(1):85–96.
111. Fink JB, Dhand R, Duarte AG, Jenne JW, Tobin MJ. Aerosol delivery from a metered-dose inhaler during mechanical ventilation. An in vitro model. Am J Respir Crit Care Med. 1996;154(2 Pt 1):382–7.
112. Hess DR, Dillman C, Kacmarek RM. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive Care Med. 2003;29(7):1145–50.
113. Mazela J, Polin RA. Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur J Pediatr. 2011;170(4):433–44.
114. Diot P, Morra L, Smaldone GC. Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1391–4.
115. Fink JB, Dhand R, Grychowski J, Fahey PJ, Tobin MJ. Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors. Am J Respir Crit Care Med. 1999;159(1):63–8.
116. Sood BG, Latif Z, Shen Y, et al. Aerosol delivery during high frequency jet ventilation: an MRI evaluation. Respir Care. 2012;57(11):1901–7.
117. Baleine J, Milesi C, Mesnage R, et al. Intubation in the delivery room: experience with nasal midazolam. Early Hum Dev. 2014;90(1):39–43.
118. Sharma R, Harish R. Comparative study on the efficacy of intranasal midazolam vs intravenous midazolam in convulsing neonates and children. Res Rev J Med Health Sci. 2013;2(4):54–7.
119. Chiaretti A, Barone G, Rigante D, et al. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child. 2011;96(2):160–3.
120. Keane EF. Another way to administer antiepileptic medications in infants and children. MCN Am J Matern Child Nurs. 1993;18(5):270–4.
121. Graves NM, Kriel RL. Rectal administration of antiepileptic drugs in children. Pediatr Neurol. 1987;3(6):321–6.
122. van Lingen RA, Deinum JT, Quak JM, et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 1999;80(1):F59–63.
123. Anderson BJ, Holford NH, Woolard GA. Paracetamol kinetics in neonates. Anaesth Intensive Care. 1997;25:721–2.
124. Hopkins CS, Underhill S, Booker PD. Pharmacokinetics of paracetamol after cardiac surgery. Arch Dis Child. 1990;65(9):971–6.
125. Keinanen S, Hietula M, Simila S, Kouvalainen K. Antipyretic therapy. Comparison of rectal and oral paracetamol. Eur J Clin Pharmacol. 1977;12(1):77–80.
126. Arana A, Morton NS, Hansen TG. Treatment with paracetamol in infants. Acta Anaesthesiol Scand. 2001;45(1):20–9.
127. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol. 2000;50(2):125–34.
128. Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013;23(5):251–61.
129. Slomkowski S, Aleman JV, Gilbert RG, et al. Terminology of polymers and polymerization processes in dispersed systems (IUPAC recommendations 2011). Pure Appl Chem. 2011;83(12):2229–59.
130. Amirav I, Newhouse MT, Luder A, Halamish A, Omar H, Gorenberg M. Feasibility of aerosol drug delivery to sleeping infants: a prospective observational study. BMJ Open. 2014;4(3):e004124.
131. Dvorak M. Medicine dispensing pacifier. US Patent 5,512,047; 1996.
132. Noble DE. Medication dispensing pacifier. US Patent 5,078,734; 1992.
133. Luehne-Porath L. Medicine dispensing pacifier. US Patent D445,902; 2001.
134. Dumont KE, Dumont D. Medication dispensing pacifier. US Patent D476,085; 2003.
135. Brenner V. Infant medicine dispenser. US Patent 2,013,009,0595; 2013.
136. Walsh J, Bickmann D, Breitkreutz J, Chariot-Goulet M. Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm. 2011;415(1–2):221–31.
137. Kraus DM, Stohlmeyer LA, Hannon PR, Freels SA. Effectiveness and infant acceptance of the Rx medibottle versus the oral syringe. Pharmacotherapy. 2001;21(4):416–23.
138. Purswani MU, Radhakrishnan J, Irfan KR, Walter-Glickman C, Hagmann S, Neugebauer R. Infant acceptance of a bitter-tasting liquid medication: a randomized controlled trial comparing the Rx medibottle with an oral syringe. Arch Pediatr Adolesc Med. 2009;163(2):186–8.
139. Foinard A, Decaudin B, Barthelemy C, Debaene B, Odou P. Prevention of drug delivery disturbances during continuous intravenous infusion: an in vitro study on a new multi-lumen infusion access device. Ann Fr Anesth Reanim. 2013;32(9):e107–12.
140. World Health Organization. Report of the informal expert meeting on dosage forms of medicines for children. Geneva: World Health Organization; 2008.
141. Kayitare E, Vervaet C, Ntawukulilyayo JD, Seminega B, Bortel V, Remon JP. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm. 2009;370(1–2):41–6.
142. Laulicht B, Langer R, Karp JM. Quick-release medical tape. Proc Natl Acad Sci U S A. 2012;109(46):18803–8.
143. Huang NN, High RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr. 1953;42(6):657–8.